ArriVent BioPharma (NASDAQ:AVBP) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of ArriVent BioPharma (NASDAQ:AVBP) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

Several other brokerages have also recently issued reports on AVBP. Guggenheim lowered their price objective on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday. JonesTrading cut their target price on shares of ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday. Citigroup reduced their target price on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a research report on Tuesday, September 22nd. Finally, Jefferies Financial Group set a $18.00 price target on ArriVent BioPharma in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.44.

ArriVent BioPharma Stock Up 0.1%

Shares of ArriVent BioPharma stock opened at $16.73 on Friday. The business has a fifty day simple moving average of $28.76 and a 200-day simple moving average of $29.26. ArriVent BioPharma has a fifty-two week low of $11.36 and a fifty-two week high of $35.83. The firm has a market cap of $824.96 million, a price-to-earnings ratio of -4.62 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP) last released its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). Analysts anticipate that ArriVent BioPharma will post -4.05 earnings per share for the current fiscal year.

Institutional Trading of ArriVent BioPharma

Hedge funds have recently bought and sold shares of the company. Tema ETFs LLC purchased a new stake in shares of ArriVent BioPharma in the 2nd quarter valued at approximately $1,981,000. Deutsche Bank AG acquired a new stake in ArriVent BioPharma during the 2nd quarter valued at $1,361,000. Dimensional Fund Advisors LP raised its stake in ArriVent BioPharma by 758.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 126,525 shares of the company’s stock valued at $2,918,000 after purchasing an additional 111,782 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of ArriVent BioPharma in the second quarter valued at $3,798,000. Finally, Bank of America Corp DE lifted its holdings in shares of ArriVent BioPharma by 41.9% in the first quarter. Bank of America Corp DE now owns 80,208 shares of the company’s stock valued at $1,850,000 after purchasing an additional 23,687 shares in the last quarter. 9.48% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for ArriVent’s third quarter and full-year 2026, as well as the first, second and third quarters of 2027. The firm also increased its FY2027 forecast to a loss of $3.97 per share from a projected loss of $4.24, indicating expectations for narrower losses over time.
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $27 price target. That target implies meaningful upside from the stock’s recent trading level and may help support investor sentiment.
• Neutral Sentiment: The estimate revisions were not uniformly positive: HC Wainwright lowered its Q4 2027 EPS forecast to a loss of $1.02 from $0.93. The company remains unprofitable, with consensus estimates calling for a $4.11-per-share loss for the current year.
• Negative Sentiment: Separate reports said HC Wainwright cut its price target for ArriVent, while Wall Street Zen lowered its stock rating. These actions could weigh on the shares despite HC Wainwright’s continued Buy recommendation. ArriVent BioPharma Stock Price Target Cut by HC Wainwright ArriVent BioPharma Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Citigroup and JonesTrading were also reported to issue pessimistic forecasts for AVBP, adding to the cautious analyst backdrop. Citigroup Issues Pessimistic Forecast for ArriVent BioPharma JonesTrading Issues Pessimistic Forecast for ArriVent BioPharma

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.